12.12.24 -- Are We Witnessing A New "Age Of The CDMO"?

Drugs have become more lipophilic and complex in structure over time. Innovative strategies are needed to improve the bioavailability of these new drugs.

Discover why BFS technology has been gaining increasing worldwide acceptance in the parenteral drug marketplace, replacing traditional glass vial processing in a growing number of applications.

Since life science professionals hail from diverse backgrounds, educations, and work experiences, different mentorship models serve their varied development needs and learning styles.

Kimberly Shepard, Ph.D., principal engineer in R&D, addresses the challenges associated with spray-drying late-stage lung cancer treatments, including proteins, peptides, and mAbs.

Review the evolving regulations for entering China's medical device market, and learn how collaborating with experts can help position your company to capitalize on this dynamic market.

When drug and API manufacturers decide to make the shift to bring production back to the U.S., they should be prepared with a well-designed quality system and a thorough tech transfer process.

The COVID-19 crisis acted as a catalyst for digital transformation in the healthcare industry. See how this transformation has impacted trends and new possibilities in the life sciences.

Gain expert insights into nitrosamine regulations, and discover practical strategies for ensuring compliance and safeguarding product safety.

Relying on fragmented data becomes problematic when teams need to dissect cell line performance data and that data is not in a digital backbone.

Digitalization leaders share valuable insights on how some life sciences manufacturers are successfully scaling their Pharma 4.0 initiatives beyond the pilot stage and paving the way forward.

Learn about the critical changes in the Annex 1 guidance from a process equipment provider's perspective, several areas where process and product change could take place, and more.

Precision powder microdosing makes it possible to quickly get formulations to the clinic, saving time, money, and use of limited APIs.

Leveraging the expertise and experience of a trusted partner can reduce risk and accelerate the time to market for drug-device combination products by creating an optimal validation master plan.

How can pharma companies secure the supply of vital APIs and intermediates and maintain consistent manufacturing costs? These steps minimize supply chain insecurity in a rapidly changing market.

Industry experts answer attendees' questions from a recent webinar about sustainability concerns surrounding oligonucleotide manufacturing.

Find out how biopharmaceutical companies can de-risk the launch process by choosing a suitable autoinjector technology and partner.

Explore the importance of isolators in the pharmaceutical and biotech industries, the challenges of innovating aseptic isolator design, best practices, and key aspects of design optimization.

Investigations into viable air excursions are difficult to perform using traditional methods. Discover why a real-time viable particle counter is key to providing process improvement.